Navigation Links
ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
Date:3/16/2010

ADVENTRX's net loss applicable to common stock for the fourth quarter of 2009 was $6.5 million, or $0.04 per share, compared to a net loss applicable to common stock of $7.5 million, or $0.08 per share, for the same period in 2008. Included in the net loss applicable to common stock for the fourth quarter of 2009 was a non-cash, deemed dividend expense of $3.3 million incurred in connection with the Company's October 2009 equity financing.

Research and development (R&D) expenses for the fourth quarter of 2009 were $2.0 million, a decrease of $2.9 million, or 59%, compared to $4.8 million for the same period in 2008. The decrease primarily was due to a $1.5 million decrease in expenses related to external research-related manufacturing and regulatory and quality assurance activities related to ANX-530 and ANX-514, a $0.7 million decrease in personnel costs, a $0.6 million decrease in external clinical trial expenses related to ANX-514 and a $0.1 million decrease in non-cash, stock-based compensation expenses.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. ADVENTRX Receives Brand Name Acceptance for ANX-530
2. ADVENTRX Receives Refuse to File Letter from FDA on ANX-530 New Drug Application
3. ADVENTRX Announces Management Promotions
4. ADVENTRX Appoints Icahn Representative to Board of Directors
5. ADVENTRX Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference on February 9
6. ADVENTRX Pharmaceuticals to Present at the Lippert/Heilshorn Life Sciences Virtual Conference
7. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
8. ADVENTRX Pharmaceuticals to Present at the BIOCOM Investor Conference on October 26
9. ADVENTRX Pharmaceuticals Announces Closing of Financing
10. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015  Galmed Pharmaceuticals Ltd. ... company focused on the development and commercialization of ... liver diseases and cholesterol gallstones, today announced that ... Vice President of Clinical Operations. Mr. ... clinical operations, development and regulatory affairs.  From 2005 ...
(Date:4/1/2015)... Minn. , April 1, 2015  EnteroMedics ... devices using neuroblocking technology to treat obesity, metabolic ... the Company has entered into a partnership with ... access to vBloc® Therapy, delivered via the Maestro® ... System is approved for adults with a BMI ...
(Date:3/31/2015)... and ORANGEBURG, N.Y., March 31, 2015 Uroplasty, ... announced the completion of their merger. The merger ... of the all-stock combination creates a new medical ... April 1, 2015, Cogentix Medical, Inc. will trade ... Medical will have its U.S. headquarters in ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces the Appointment of George Tonelli as Vice President of Clinical Operations 2Galmed Pharmaceuticals Announces the Appointment of George Tonelli as Vice President of Clinical Operations 3EnteroMedics Announces Partnership with American HealthCare Lending to Support Patient Access and Enhance Affordability of vBloc Therapy 2EnteroMedics Announces Partnership with American HealthCare Lending to Support Patient Access and Enhance Affordability of vBloc Therapy 3EnteroMedics Announces Partnership with American HealthCare Lending to Support Patient Access and Enhance Affordability of vBloc Therapy 4Uroplasty and Vision-Sciences Complete Merger 2Uroplasty and Vision-Sciences Complete Merger 3Uroplasty and Vision-Sciences Complete Merger 4
... show evidence of additional protection,against infection with ... 17, 2007 /PRNewswire-FirstCall/ -- The,GlaxoSmithKline cervical cancer ... preventing precancerous,lesions due to cancer-causing human papillomavirus ... years in an extended follow-up trial, according ...
... Alnylam,Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi ... for Cancer,Research (AACR) 2007 Annual Meeting that ... ALN-VSP01, for the,treatment of liver cancer and ... program. ALN-VSP01 is an RNAi therapeutic that ...
Cached Medicine Technology:Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100,Percent Protection Against Precancerous Lesions Caused By,Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than,Five Years 2Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100,Percent Protection Against Precancerous Lesions Caused By,Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than,Five Years 3Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100,Percent Protection Against Precancerous Lesions Caused By,Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than,Five Years 4Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100,Percent Protection Against Precancerous Lesions Caused By,Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than,Five Years 5Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 2Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 3Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 4Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 5
(Date:4/1/2015)... SCI Solutions , the health industry’s ... that CEO Joel French will be a featured speaker ... in Chicago, April 12-16, 2015. French will co-present ... Coordination Strategies ” with Northeast Georgia Health System (NGHS) ... than 38,000 healthcare industry professionals are expected at the ...
(Date:4/1/2015)... 2015 Dr Roz Kamani, a Vancouver ... now offering her patients an opportunity to learn more ... in “Beauty Days”, which is an exclusive VIP event ... Kitsilano Skin Care Clinic. It is attended by Dr ... the latest products and services that are on offer. ...
(Date:4/1/2015)... Diego, CA (PRWEB) April 01, 2015 ... organization, is announcing two continuing medical education (CME) ... is to help practitioners become more confident in ... prevent disease. After completion of these CME courses, ... , The CME courses available are “Vitamin ...
(Date:4/1/2015)... April 01, 2015 Tempaper has joined ... new virtual giving campaign that will raise critical funds ... fighting muscle disease across the United States. , Throughout ... through Tempaperdesigns.com will automatically receive free domestic ... strength and urgently needed progress to children and adults ...
(Date:4/1/2015)... Like a mosaic slowly gaining definition and becoming ... potential causes of rosacea. April has been designated as ... to educate the public on the warning signs of ... affect more than 16 million Americans. , The ... its patient-funded research grants program, awarding $1.4 million to ...
Breaking Medicine News(10 mins):Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 2Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 3Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 4Health News:Dr Roz Kamani Now Offers Patients The Opportunity to Learn About Latest Products and Services 2Health News:GrassrootsHealth Launches CME Courses about Vitamin D 2Health News:GrassrootsHealth Launches CME Courses about Vitamin D 3Health News:Tempaper and MDA Team up in the Fight Against Muscle Disease 2Health News:Tempaper and MDA Team up in the Fight Against Muscle Disease 3Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 2Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 3Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 4Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 5
... Sudden Cardiac,Arrest Through Public Education and Advocacy, WASHINGTON, ... today that it has incorporated Iowa AED Access,for All ... local organizations to,help carry out its mission of preventing ... is led by Mary Tappe of Ankeny, Iowa, who ...
... 8 The Department of Labor,s,Occupational Safety and ... for the review of its methylene chloride (MC),Standard ... announced in,the July 10, 2007, Federal Register (72 ... Standard in 1997 to protect employees from occupational,exposure ...
... effects include gastrointestinal problems, anxiety , , TUESDAY, Jan. ... helped people shed pounds, but its adverse effects ... , Called taranabant, the drug was developed by ... published in the January issue of Cell ...
... advised to cut out sucrose (table sugar) all together. However, ... some researchers who suggest that moderate amounts of sugar can ... with diabetes. Now a new study has been published that ... who increased their daily sugar intake (in the form of ...
... the latest cutting-edge findings in laboratory, translational and ... on innovative research, novel technologies, life-saving therapies in ... cancer prevention. , To help you plan your ... related scientific abstracts will be available online at ...
... First System Purchased for Installation in Bangalore, ... ARAY ), a global leader in the field ... has purchased a,CyberKnife(R) Robotic Radiosurgery System for its ... June 2008, this will be the first,CyberKnife System ...
Cached Medicine News:Health News:Sudden Cardiac Arrest Association Launches Iowa Affiliate 2Health News:Sudden Cardiac Arrest Association Launches Iowa Affiliate 3Health News:OSHA Extends Comment Period for Lookback Review of Methylene Chloride Standard 2Health News:New Weight-Loss Drug Shows Promise in Early Study 2Health News:New Weight-Loss Drug Shows Promise in Early Study 3Health News:Carrot cake study on sugar in type 2 diabetes 2Health News:CyberKnife Radiosurgery Expands to India 2Health News:CyberKnife Radiosurgery Expands to India 3
Ethicon, medium clip size, 10mm, rotatable take apart...
Solid phase capture sandwich ELISA assay using a microwell format....
The C-Reactive Protein (CRP) assay is used for the quantitative analysis of C-reactive protein in human serum and plasma. Kit is for use with the Abbot Laboratories Aeroset, ARCHITECT c8000 or ARCHI...
... broad menu clinical chemistry analyzer designed for ... Care givers can now perform routine multi-chemistry ... minute of hands-on time. Complete panel results ... expensive laboratory analyzers are available in under ...
Medicine Products: